The Competition Justifies our Business Model

Although we have the most unique enterprise model of its kind in the pharmaceutical space, after Blockchain BioPharma launched, two competitors did launch after, which we expected.
Blockchain BioPharma is the first PHARMA Company of its kind, and while we see competition brewing with the publication of our #Research, we also see this type of business as a "Blue Ocean" that can make more profits, if the global PHARMA companies work with us, should they decide to join forces on our platform. It may be hard, the Pharmaceutical industry is highly conservative, by design.
  1. 1.
    Molecule.to: Based in Germany and co-founded by former Linux executives, Molecule appears to have launched an NFT Marketplace already.
  2. 2.
    Pharmalyse Finance: Appears to only have a Medium Site for now, and appears to be mainly R&D, just as Blockchain BioPharma was in the beginning.
COMPETITIVE ADVANTAGE
  1. 1.
    Blockchain BioPharma has better branding
  2. 2.
    Blockchain BioPharma has a more advanced architecture
  3. 3.
    Blockchain BioPharma is a #Data Company First, DeFi is only a part of that data.